Brief: Oxford Cannabinoid Says MHRA & Wales REC 2 Approve Phase I Clinical Trial Application For OCT461201

Oxford Cannabinoid Technologies Holdings

17/05/2023 07:52

May 17 (Reuters) - Oxford Cannabinoid Technologies
Holdings PLC  OCTP.L :
    * OXFORD CANNABINOID  - MHRA & REC 2 APPROVAL FOR PHASE 1
CLINICAL
TRIAL
    * OXFORD CANNABINOID TECHNOLOGIES - WALES RESEARCH ETHICS
COMMITTEE 2 HAVE APPROVED CO'S COMBINED PHASE I CLINICAL TRIAL
APPLICATION FOR OCT461201
    * OXFORD CANNABINOID TECHNOLOGIES - PHASE I FIRST-IN-HUMAN
CLINICAL TRIAL BEING CONDUCTED IN UK IN HEALTHY VOLUNTEERS, WITH
SINGLE ASCENDING DOSE PROTOCOL
    * OXFORD CANNABINOID TECHNOLOGIES HOLDINGS PLC - PARTICIPANT
ENROLMENT WILL BEGIN IMMEDIATELY, AND TRIAL IS EXPECTED TO BE
COMPLETED DURING Q3 2023

Source text for Eikon:  ID:nRSQ6489Za 
Further company coverage:  OCTP.L 

 ((Reuters.Briefs@thomsonreuters.com;))